Endocrine resistance remains a key challenge in HR+/HER2- advanced breast cancer, particularly after progression on CDK4/6 inhibitors. The CAPItello-291 trial, published in The New England Journal of Medicine (2023), highlighted…

The Phase II AveNEC trial, published in Clinical Cancer Research (February 2025), evaluated avelumab in patients with high-grade neuroendocrine neoplasms (NEN G3) who had progressed after prior chemotherapy. The study…

The BREAKWATER phase 3 trial, published in Nature Medicine, has demonstrated that encorafenib plus cetuximab (EC) with mFOLFOX6 significantly improves objective response rates compared to standard chemotherapy in BRAF V600E-mutant metastatic colorectal cancer (mCRC). The study reports a confirmed objective response rate of 60.9% with EC+mFOLFOX6 compared to 40.0% with standard chemotherapy, with a median duration of response of 13.9 months versus 11.1 months. The interim analysis of overall survival shows a hazard ratio of 0.47, suggesting a clear survival benefit for EC+mFOLFOX6.

A new study published in Cancer Cell, provides key insights into the role of the interferon-high (IFN-high) immunophenotype in predicting response to immune checkpoint inhibition (ICI) in colorectal cancer (CRC). By analyzing tumor microenvironment features, the study identifies a subset of both mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) CRCs that exhibit an IFN-high profile, marked by cytotoxic T cells and antigen-presenting macrophages.

The IMPROVE trial, a phase II study investigating intermittent versus continuous panitumumab plus FOLFIRI in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC), has provided key insights into optimizing first-line treatment strategies.

Recent research led by Professor Julien Taieb and colleagues provides significant advancements in the prognostic assessment of stage III colon cancer by integrating circulating tumor DNA (ctDNA) and Immunoscore (IS). This post hoc analysis of the PRODIGE-GERCOR IDEA-France and HORG-IDEA-Greece trials demonstrates that ctDNA serves as an independent prognostic marker, while IS provides additional stratification, particularly in ctDNA-negative patients.

A groundbreaking study published in JCO introduces novel prognostic models leveraging transcriptomic signatures of the tumor microenvironment (TME) and cell cycle to enhance risk stratification in stage III colon cancer. Using data from the PETACC-8 and IDEA-France trials, researchers identified key markers, including T-cell and macrophage M2 signatures, CXCL13 expression, and an Oncotype-like recurrence score.